| 1 |
Wilson GC, Freeman CM, Kuethe JW, et al. CXC chemokine receptor-4 signaling limits hepatocyte proliferation after hepatic ischemia-reperfusion in mice [J]. Am J Physiol Gastrointest Liver Physiol, 2015, 308: G702-G709.
|
| 2 |
Pawig L, Klasen C, Weber C, et al. Diversity and inter-connections in the CXCR4 chemokine receptor/ligand family:molecular perspectives [J]. Front Immunol, 2015, 6: 429.
|
| 3 |
Lu C, Zhang Y, Sun C, et al. Stromal cell derived factor-1 promotes hepatic insulin resistance via inhibiting hepatocyte lipophagy [J]. J Cell Mol Med, 2025; 29(2): e70352.
|
| 4 |
Nagasawa T, Hirota S, Tachibana K, et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1 [J]. Nature, 1996, 382: 635-638.
|
| 5 |
Yoshie O, Imai T, Nomiyama H. Chemokines in immunity [J]. AdvImmunol, 2001, 78: 57-110.
|
| 6 |
Loetscher M, Geiser T, O'Reilly T, et al. Cloning of a human seven transmembrane domain receptor, LESTR, that is highly expressed in leukocytes [J]. J Biol Chem, 1994, 269: 232-237.
|
| 7 |
Bleul CC, Farzan M, Choe H, et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry [J]. Nature, 1996, 382: 829-833.
|
| 8 |
Oberlin E, Amara A, Bachelerie F, et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1 [J]. Nature, 1996, 382: 833-835.
|
| 9 |
Ma Q, Jones D, Borghesani PR, et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4-and SDF-1-deficient mice [J]. Proc Natl Acad Sci USA, 1998, 95: 9448-9453.
|
| 10 |
Tachibana K, Hirota S, Iizasa H, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract [J]. Nature, 1998, 393: 591-594.
|
| 11 |
Libert F, Parmentier M, Lefort A, et al. Selective amplification and cloning of four new members of the G protein-coupled receptor family [J]. Science, 1989, 244(4904): 569-72.
|
| 12 |
Shimizu N, Soda Y, Kanbe K, et al. A putative G protein-coupled receptor, RDC1, is a novel coreceptor for human and simian immunodeficiency viruses [J]. J Virol, 2000, 74: 619-626.
|
| 13 |
Ding BS, Cao Z, Lis R, et al. Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis [J]. Nature, 2014, 505: 97-102.
|
| 14 |
DeLeve LD, Wang X, Wang L. VEGF-sdf1 recruitment of CXCR7+bone marrow progenitors of liver sinusoidal endothelial cells promotes rat liver regeneration [J]. Am J Physiol Gastrointest Liver Physiol, 2016, 310: G739-G746.
|
| 15 |
Jaeschke H. Molecular mechanisms of hepatic ischemia-reperfusion injury and preconditioning [J]. Am J Physiol Gastrointest Liver Physiol, 2003, 284: G15-G26.
|
| 16 |
Ito C, Haraguchi R, Ogawa K, et al. Demethylation in promoter region of severely damaged hepatocytes enhances chemokine receptor CXCR4 gene expression [J]. Histochem Cell Biol, 2023, 160(5): 407-418.
|
| 17 |
Otaka F, Ito Y, Nakamoto S, et al. Macrophages contribute to liver repair after monocrotaline-induced liver injury via SDF-1/CXCR4 [J]. Experimental and therapeutic medicine, 2021, 22(1): 668.
|
| 18 |
Zheng J, Li H, He L, et al. Preconditioning of umbilical cord-derived mesenchymal stem cells by rapamycin increases cell migration and ameliorates liver ischaemia/reperfusion injury in mice via the CXCR4/CXCL12 axis [J]. Cell Prolif, 2019, 52(2): e12546.
|
| 19 |
Krzystek-Korpacka M, Fleszar MG, Fortuna P, et al. Modulation of prostanoids profile and counter-regulation of SDF-1α/CXCR4 and VIP/VPAC2 expression by sitagliptin in non-diabetic rat model of hepatic ischemia-reperfusion injury [J]. Int J Mol Sci, 2021, 22(23): 13155.
|
| 20 |
Abe Y, Uchinami H, Kudoh K, et al. Liver epithelial cells proliferate under hypoxia and protect the liver from ischemic injury via expression of HIF-1 alpha target genes [J]. Surgery, 2012, 152(5): 869-878.
|
| 21 |
Wilson GC, Freeman CM, Kuethe JW, et al. CXC chemokine receptor-4 signaling limits hepatocyte proliferation after hepatic ischemia-reperfusion in mice [J]. Am J Physiol Gastrointest Liver Physiol, 2015, 308(8): G702-G709.
|
| 22 |
Ding F, Liu Y, Li J, et al. TC14012 enhances the anti-fibrosis effects of UC-MSCs on the liver by reducing collagen accumulation and ameliorating inflammation [J]. Stem Cell Res Ther, 2024, 15(1): 44.
|
| 23 |
Chen N, Sun Y, Luo P, et al. Association of CXCR4 gene expression and promoter methylation with chronic hepatitis B-related fibrosis/cirrhosis [J]. Int Immunopharmacology, 2024, 139: 112686.
|
| 24 |
Feng Y, Broder CC, Kennedy PE, et al. HIV-1 entry cofactor:functional cDNA cloning of a seven-transmembrane,G protein-coupled receptor [J]. Science, 1996, 272: 872-877.
|
| 25 |
Hong F, Saiman Y, Si C, et al. X4 Human immunodeficiency virus type 1 gp120 promotes human hepatic stellate cell activation and collagen I expression through interactions with CXCR4 [J]. PLoS One, 2012, 7: e33659.
|
| 26 |
Saiman Y, Agarwal R, Hickman DA, et al. CXCL12 induces hepatic stellate cell contraction through a calcium-independent pathway [J]. Am J Physiol Gastrointest Liver Physiol, 2013, 305: G375-G382.
|
| 27 |
Saiman Y, Jiao J, Fiel MI, et al. Inhibition of the CXCL12/CXCR4 chemokine axis with AMD3100,a CXCR4 small molecule inhibitor,worsens murine hepatic injury [J]. Hepatol Res, 2015, 45: 794-803.
|
| 28 |
Chow LN, Schreiner P, Ng BY, et al. Impact of a CXCL12/CXCR4 antagonist inbleomycin (BLM) induced pulmonary fibrosis and carbon tetrachloride (CCl4) induced hepatic fibrosis in mice [J]. PLoS One, 2016, 11: e0151765.
|
| 29 |
Tsuchiya A, Imai M, Kamimura H, et al. Increased susceptibility to severe chronic liver damage in CXCR4 conditional knock-out mice [J]. Dig Dis Sci, 2012, 57: 2892-2900.
|
| 30 |
Liu Y, Yang X, Jing YY, et al. Contribution and Mobilization of Mesenchymal Stem Cells in a mouse model of carbon tetrachloride-induced liver fibrosis [J]. Sci Rep, 2015, 5: 17762.
|
| 31 |
Cui H, Yang W. Single-cell RNA sequencing analysis reveals potential key prognostic markers in hepatocellular carcinoma [J]. Discov Oncol, 2024, 15(1): 747.
|
| 32 |
Pan XF, Kaminga AC, Wen SW, et al. Chemokines in hepatocellular carcinoma:a meta-analysis [J]. Carcinogenesis, 2020, 41(12): 1682-1694.
|
| 33 |
Chen RX, Song HY, Dong YY, et al. Dynamic expression patterns of differential proteins during early invasion of hepatocellular carcinoma [J]. PLoS One, 2014, 9: e88543.
|
| 34 |
Zhao H, Guo LY, Zhao H, et al. CXCR4 over-expression and survival in cancer: a system review and meta-analysis [J]. Oncotarget, 2015, 6(7): 5022-5040.
|
| 35 |
Wang X, Zhang W, Ding Y, et al. CRISPR/Cas9-mediated genome engineering of CXCR4 decreases the malignancy of hepatocellular carcinoma cells in vitro and in vivo [J]. Oncol Rep, 2017, 37(6): 3565-3571.
|
| 36 |
Kun-Ming C, Chih-Hsien C, Chen-Fang L, et al. Potential anticancer effect of celastrol on hepatocellular carcinoma by suppressing CXCR4-related signal and impeding tumor growth in vivo [J]. Arch Med Res, 2020, 51(4): 297-302.
|
| 37 |
Wu WJ, Wang J, Chen F, et al. Exploration of heterogeneity and recurrence signatures in hepatocellular carcinoma [J]. Mol Ooncol, 2025, 19(8):2388-2411.
|
| 38 |
Lin L, Han MM, Wang F, et al. CXCR7 stimulates MAPK signaling to regulate hepatocellular carcinoma progression [J]. Cell Death Dis, 2014, 5(10): e1488.
|
| 39 |
Liu CH, Chan KM, Chiang T, et al. Dual-functional nanoparticles targeting CXCR4 and delivering antiangiogenic siRNA ameliorate liver fibrosis [J]. Mol Pharm, 2016, 13(7): 2253-2262.
|
| 40 |
Ullah A, Chen G, Zhang Y, et al. A new approach based on CXCR4-targeted combination liposomes for the treatment of liver fibrosis [J]. Biomater Sci, 2022, 10(10): 2650-2664.
|
| 41 |
Morita S, Lei PJ, Shigeta K, et al. Combination CXCR4 and PD-1 blockade enhances intratumoral dendritic cell activation and immune responses against hepatocellular carcinoma [J]. Cancer Immunol Res, 2025, 13(2): 162-170.
|
| 42 |
杨振林, 邹伟伟. 索拉非尼防治大鼠肝癌肝移植术后肿瘤转移复发的研究 [J/OL]. 中华临床医师杂志(电子版), 2011, 5(2): 335-342.
|
| 43 |
Steinberg M, Silva M. Plerixafor: a chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma [J]. Clin Ther, 2010, 32(5): 821-843.
|
| 44 |
Kajiyama H, Shibata K, Terauchi M, et al. Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma [J]. Int J Cancer, 2008, 122(1): 91-99.
|
| 45 |
Song JS, Chang CC, Wu CH, et al. A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment [J]. Proc Natl Acad Sci USA, 2021, 118(13): e2015433118.
|